Myositis Multidisciplinary Clinic in a Tertiary Referral Center

References

• Lundberg IE, Miller FW, Tjärnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med. 2016;280(1):39–51. doi:10.1111/joim.12524
   PubMed Web of Science ®Google Scholar
• Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109–129. doi:10.3233/JND-180308
   PubMedGoogle Scholar
• Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep. 2011;13(3):208–215. doi:10.1007/s11926-011-0169-7
   PubMed Web of Science ®Google Scholar
• Leal I, Romão VC, Mano S, et al. A non-infectious uveitis multidisciplinary clinic in a tertiary referral center: clinical impact and added value. J Multidiscip Healthc. 2021;14:695–704. doi:10.2147/JMDH.S292981
   PubMed Web of Science ®Google Scholar
• Cobo-Ibáñez T, Villaverde V, Seoane-Mato D, et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int. 2016;36(2):221–229. doi:10.1007/s00296-015-3377-z
   PubMed Web of Science ®Google Scholar
• Horvath LE, Yordan E, Malhotra D, et al. Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. J Oncol Pract. 2010;6(6):e21–6. doi:10.1200/JOP.2010.000073
   PubMedGoogle Scholar
• Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol. 2014;175(3):349–358. doi:10.1111/cei.12194
   PubMed Web of Science ®Google Scholar
• Rider LG, Aggarwal R, Machado PM, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14(5):303–318. doi:10.1038/nrrheum.2018.33
   PubMed Web of Science ®Google Scholar
• Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am. 2013;24(1):193–207. doi:10.1016/j.pmr.2012.08.017
   PubMed Web of Science ®Google Scholar
• Filli L, Maurer B, Manoliu A, Andreisek G, Guggenberger R. Whole-body MRI in adult inflammatory myopathies: do we need imaging of the trunk? Eur Radiol. 2015;25(12):3499–3507. doi:10.1007/s00330-015-3783-3
   PubMed Web of Science ®Google Scholar
• Piette Y, Reynaert V, Vanhaecke A, et al. Standardised interpretation of capillaroscopy in autoimmune idiopathic inflammatory myopathies: a structured review on behalf of the EULAR study group on microcirculation in Rheumatic Diseases. Autoimmun Rev. 2022;21(6):103087. doi:10.1016/j.autrev.2022.103087
   PubMed Web of Science ®Google Scholar
• Mugii N, Hasegawa M, Matsushita T, et al. Association between nail-fold capillary findings and disease activity in dermatomyositis. Rheumatology. 2011;50(6):1091–1098. doi:10.1093/rheumatology/keq430
   PubMed Web of Science ®Google Scholar
• Kubo S, Todoroki Y, Nakayamada S, et al. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology. 2019;58(1):120–130. doi:10.1093/rheumatology/key257
   PubMed Web of Science ®Google Scholar
• Opinc A, Brzezińska O, Makowska J. Underdiagnosis of cardiopulmonary involvement in patients with idiopathic inflammatory myopathies. Reumatologia. 2021;59(5):276–284. doi:10.5114/reum.2021.110609
   PubMed Web of Science ®Google Scholar
• ACR Meeting Abstracts. Cancer screening recommendations for patients with idiopathic inflammatory myopathy [Internet]; 2022. Available from: https://acrabstracts.org/abstract/cancer-screening-recommendations-for-patients-with-idiopathic-inflammatory-myopathy/. Accessed April 19, 2023.
   Google Scholar
• Santos MJ, Canhão H, Mourão AF, et al. Reuma.pt contribution to the knowledge of immune-mediated systemic rheumatic diseases. Acta Reumatol Port. 2017;42(3):232–239.
   PubMed Web of Science ®Google Scholar
• Canhão H, Faustino A, Martins F, Fonseca JE. Rheumatic Diseases Portuguese Register Board Coordination, Portuguese Society of Rheumatology. Reuma.pt - the rheumatic diseases Portuguese register. Acta Reumatol Port. 2011;36(1):45–56.
   PubMed Web of Science ®Google Scholar
• Our Network | ERN ReCONNET. European reference network on rare and complex connective tissue and musculoskeletal diseases [Internet]; 2022. Available from: https://reconnet.ern-net.eu/our-network/. Accessed April 19, 2023.
   Google Scholar
• Martins P, Dourado E, Melo AT, et al. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome. ARP Rheumatol. 2022;1(ARP Rheumatology, n°3 2022):190–196.
   PubMedGoogle Scholar
• Bandeira M, Di Cianni F, Marinello D, et al. An overlook on the current registries for rare and complex connective tissue diseases and the future scenario of TogethERN ReCONNET. Front Med. 2022;9:889997. doi:10.3389/fmed.2022.889997
   Web of Science ®Google Scholar
• Bandeira M, Vieira A, Guimarães V, et al. Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. Clin Exp Rheumatol. 2022;40(5):32–39. doi:10.55563/clinexprheumatol/v1e7s2
   PubMed Web of Science ®Google Scholar
• Nascimento J, Tenazinha C, Campanilho-Marques R, Cordeiro I, Salgado S. Rituximab in the treatment of anti-MDA5 dermatomyositis-associated interstitial lung disease: a case-based literature review. ARP Rheumatol. 2022;1(2):168–173.
   PubMedGoogle Scholar
• Cavagna L, Meloni F, Meyer A, et al. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. Clin Exp Rheumatol. 2022;40(2):274–283. doi:10.55563/clinexprheumatol/di1083
   PubMed Web of Science ®Google Scholar
• Abouyahya I, Liem SIE, Amoura Z, et al. Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. Clin Exp Rheumatol. 2022;40(5):66–70. doi:10.55563/clinexprheumatol/x5aras
   PubMed Web of Science ®Google Scholar
• Palermo BL, Bottazzi F, Dourado E, et al. Capillary leak syndrome in a patient with cancer-associated anti-transcriptional intermediary factor 1γ dermatomyositis treated with rituximab. Clin Exp Rheumatol. 2022;40(5):118–120. doi:10.55563/clinexprheumatol/j26b6o
   PubMed Web of Science ®Google Scholar
• Campanilho-Marques R, Deakin CT, Simou S, et al. Retrospective analysis of infliximab and Adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22(1):79. doi:10.1186/s13075-020-02164-5
   PubMed Web of Science ®Google Scholar
• Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13(4–5):367–371. doi:10.1016/j.autrev.2014.01.022
   PubMed Web of Science ®Google Scholar
• Deakin CT, Campanilho-Marques R, Simou S, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol. 2018;70(5):785–793. doi:10.1002/art.40418
   PubMed Web of Science ®Google Scholar
• Campanilho-Marques R, Almeida B, Deakin C, et al. Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with juvenile dermatomyositis. Arthritis Care Res. 2016;68(10):1514–1521. doi:10.1002/acr.22867
   Web of Science ®Google Scholar
• Almeida B, Campanilho-Marques R, Arnold K, et al. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheumatol. 2015;67(9):2495–2502. doi:10.1002/art.39200
   PubMed Web of Science ®Google Scholar
• Wagner EH. Effective teamwork and quality of care. Med Care. 2004;42(11):1037–1039. doi:10.1097/01.mlr.0000145875.60036.ed
   PubMed Web of Science ®Google Scholar
• Alexanderson H. Exercise in myositis. Curr Treat Options Rheumatol. 2018;4(4):289–298. doi:10.1007/s40674-018-0113-3
   PubMedGoogle Scholar
• Alemo Munters L, Dastmalchi M, Katz A, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther. 2013;15(4):R83. doi:10.1186/ar4263
   PubMed Web of Science ®Google Scholar
• Pipitone N, Salvarani C. Treatment of inflammatory myopathies. Expert Rev Clin Immunol. 2018;14(7):607–621. doi:10.1080/1744666X.2018.1491307
   PubMed Web of Science ®Google Scholar
• DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267–281. doi:10.1016/j.jaad.2019.06.1309
   PubMed Web of Science ®Google Scholar
• Meyer A, Sibilia J. Strategy for suspected myositis. Joint Bone Spine. 2019;86(5):568–575. doi:10.1016/j.jbspin.2019.01.013
   PubMed Web of Science ®Google Scholar
• Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013;88(1):83–105. doi:10.1016/j.mayocp.2012.10.017
   PubMed Web of Science ®Google Scholar
• Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2017;21(2):131–136. doi:10.1177/1203475416665601
   PubMed Web of Science ®Google Scholar
• Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021;51(6):845–852. doi:10.1111/imj.15358
   PubMed Web of Science ®Google Scholar
• van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis. 2022;16:17534666221117002. doi:10.1177/17534666221117002
   Web of Science ®Google Scholar